These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35501622)

  • 1. Comparison of [
    Stokke C; Nørgaard JN; Feiring Phillips H; Sherwani A; Nuruddin S; Connelly J; Schjesvold F; Revheim ME
    Mol Imaging Biol; 2022 Oct; 24(5):842-851. PubMed ID: 35501622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers.
    Ulaner GA; Goldman DA; Gönen M; Pham H; Castillo R; Lyashchenko SK; Lewis JS; Dang C
    J Nucl Med; 2016 Sep; 57(9):1350-6. PubMed ID: 26940766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine receptor-4 targeted PET/CT with
    Pan Q; Cao X; Luo Y; Li J; Feng J; Li F
    Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):537-546. PubMed ID: 31776631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-3-18F-FACBC (18F-Fluciclovine) PET/CT of Breast Cancer: An Exploratory Study.
    Tade FI; Cohen MA; Styblo TM; Odewole OA; Holbrook AI; Newell MS; Savir-Baruch B; Li X; Goodman MM; Nye JA; Schuster DM
    J Nucl Med; 2016 Sep; 57(9):1357-63. PubMed ID: 27056619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging CXCR4 receptors expression for staging multiple myeloma by using
    Shekhawat AS; Singh B; Malhotra P; Watts A; Basher R; Kaur H; Hooda M; Radotra BD
    Br J Radiol; 2022 Aug; 95(1136):20211272. PubMed ID: 35731811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coefficient of variation and texture analysis of 18F-FDG PET/CT images for the prediction of outcome in patients with multiple myeloma.
    Pellegrino S; Origlia D; Di Donna E; Lamagna M; Della Pepa R; Pane F; Del Vecchio S; Fonti R
    Ann Hematol; 2024 Sep; 103(9):3713-3721. PubMed ID: 39046513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
    Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
    Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.
    Cassou-Mounat T; Balogova S; Nataf V; Calzada M; Huchet V; Kerrou K; Devaux JY; Mohty M; Talbot JN; Garderet L
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1995-2004. PubMed ID: 27121691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [
    Zanoni L; Bianchi L; Nanni C; Pultrone C; Giunchi F; Bossert I; Matti A; Schiavina R; Fiorentino M; Romagnoli D; Fonti C; Lodi F; D'Errico A; Brunocilla E; Porreca A; Fanti S
    Eur J Nucl Med Mol Imaging; 2021 Dec; 49(1):390-409. PubMed ID: 34213609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of semi-quantitative parameters of
    Wan B; Zhang S; Wang P; Deng P; Dai W
    Ann Nucl Med; 2023 Mar; 37(3):155-165. PubMed ID: 36528697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma.
    Cengiz A; Arda HÜ; Döğer F; Yavaşoğlu İ; Yürekli Y; Bolaman AZ
    Turk J Haematol; 2018 Aug; 35(3):175-180. PubMed ID: 29806594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment response evaluation with
    Sachpekidis C; Hillengass J; Goldschmidt H; Wagner B; Haberkorn U; Kopka K; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):50-62. PubMed ID: 27573638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Initial Experience with the Radiotracer 18F-Fluciclovine PET/CT in Ovarian Cancer.
    Buehner TM; Liotta M; Potkul RK; Wagner RH; Savir-Baruch B
    Mol Imaging Biol; 2024 Feb; 26(1):45-52. PubMed ID: 36754935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The potential utility of [
    Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET/CT studies of multiple myeloma using (18) F-FDG and (18) F-NaF: comparison of distribution patterns and tracers' pharmacokinetics.
    Sachpekidis C; Goldschmidt H; Hose D; Pan L; Cheng C; Kopka K; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1343-53. PubMed ID: 24562650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of [68Ga]-FAPI PET/CT and [18F]-FDG PET/CT in Multiple Myeloma: Clinical Experience.
    Elboga U; Sahin E; Cayirli YB; Okuyan M; Aktas G; Haydaroglu Sahin H; Dogan I; Kus T; Akkurd DM; Cimen U; Mumcu V; Kilbas B; Celen YZ
    Tomography; 2022 Feb; 8(1):293-302. PubMed ID: 35202189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid simultaneous whole-body 2-[
    Jamet B; Carlier T; Bailly C; Bodet-Milin C; Monnet A; Frampas E; Touzeau C; Moreau P; Kraeber-Bodere F
    Eur Radiol; 2023 Sep; 33(9):6438-6447. PubMed ID: 37022439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Bone Lesions in Myeloma Before and During Anticancer Therapy Using
    Nakuz TS; Millinger FP; El-Rabadi K; Weber M; Pichler V; Wadsak W; Mitterhauser M; Haug A; Hacker M; Karanikas G; Pietschmann P; Agis H
    Anticancer Res; 2019 Apr; 39(4):1943-1952. PubMed ID: 30952737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.